02-28-2022, 05:27 PM
|
#1134
|
Franchise Player
|
Quote:
Novavax Inc NVAX.O said on Monday that an extended analysis of a late-stage study conducted in the United Kingdom showed that its COVID-19 vaccine provided long-term protection against the coronavirus.
The protein-based vaccine, NVX-CoV2373, continued to provide protection and maintained overall efficacy of 82.7% over a six-month period, the company said.
Additionally, vaccine efficacy of 82.5% was maintained against both symptomatic and asymptomatic infection, while vaccine efficacy against severe disease was 100%.
The analysis was conducted between November 2020 and May 2021 before the Delta and Omicron variants became dominant.
|
https://www.ctvnews.ca/health/corona...rial-1.5799676
|
|
|